TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20571241

Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no clamping)
Number of subjects: 25
Study: 18665018

Group type: EXPERIMENTAL
Intervention: Two-part brief counseling intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study: 15817850

Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein (LF-HP) diet (29 ± 1% fat, 34 ± 0.8% protein)
Number of subjects: 57

Group type: COMPARATOR
Intervention: High-fat, standard-protein (HF-SP) diet (45 ± 0.6% fat, 18 ± 0.3% protein)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 57
Study: 12613519

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment with average dose of 174 mg/m2 (median 200 mg/m2) and mediastinum irradiation dose of 21 Gy (median 30 Gy)
Number of subjects: 88
Study: 9750444

Group type: EXPERIMENTAL
Intervention: 7 g of tranexamic acid after induction of anesthesia and 3 g after CPB (group T)
Number of subjects: 28
Study: 7625419

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg for 2 years
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 2778913

Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 354736

Group type: EXPERIMENTAL
Intervention: Conventional bowel preparation (CBP) using oral magnesium sulphate, enemas and rectal washouts
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Whole bowel irrigation (WBI) via a nasogastric tube
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral neomycin and metronidazole for 48 h before operation added to all three methods of bowel preparation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no bowel preparation)
Number of subjects: 88
Study: 31805256

Group type: EXPERIMENTAL
Intervention: Low-dose NL003
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Middle-dose NL003
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dose NL003
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 29748353

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HD-ER)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen
Number of subjects: 21105
Study: 27297209

Group type: EXPERIMENTAL
Intervention: Novel microbial lipase (NM-BL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24738517

Group type: EXPERIMENTAL
Intervention: Active ethics training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Passive ethics training (Control)
Number of subjects: 72
Study: 22267467

Group type: EXPERIMENTAL
Intervention: RBV dose ≥3.0 g/kg
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: RBV dose <3.0 g/kg
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: RBV dose >3.0 g/kg
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Undetectable HCV RNA at week 4
Number of subjects: 951
Study: 20007431

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 31
Study: 17622279

Group type: EXPERIMENTAL
Intervention: Interactive video game exercise (combined with stationary cycling)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional aerobic training (stationary cycling alone)
Number of subjects: 14
Study: 15908667

Group type: EXPERIMENTAL
Intervention: Cisplatin plus fluorouracil (CF)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Cisplatin plus paclitaxel (CP)
Number of subjects: 218
Study: 12392039

Group type: EXPERIMENTAL
Intervention: BiDil (a fixed combination of hydralazine and isosorbide dinitrate)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 9836106

Group type: EXPERIMENTAL
Intervention: Faecal elastase-1 assay in coeliac patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Secretin‐caerulein test in coeliac patients
Number of subjects: 30
Study: 8008785

Group type: EXPERIMENTAL
Intervention: Autogenic training (relaxation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Quiet rest (control)
Number of subjects: 16
Study: 2480639

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11
Study: 19382124

Group type: EXPERIMENTAL
Intervention: 200 microl lavender capsules
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 97
Study: 484753

Group type: EXPERIMENTAL
Intervention: High-priority men receiving more invitations to be screened
Number of subjects: 18872

Group type: EXPERIMENTAL
Intervention: Demographic characteristics and risk factor variables (blood pressure, blood cholesterol, cigarette smoking levels)
Number of subjects: 18872

Group type: EXPERIMENTAL
Intervention: Whether or not a man received a medical care service within the preceding two years
Number of subjects: 18872
Study: 31028746

Group type: EXPERIMENTAL
Intervention: STRONGkids tool
Number of subjects: 271

Group type: COMPARATOR
Intervention: Anthropometric measurements
Number of subjects: 271
Study: 30979559

Group type: COMPARATOR
Intervention: Group A (myopic non-glaucomatous individuals)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Group B (myopic glaucoma patients)
Number of subjects: 62
Study: 28279391

Group type: EXPERIMENTAL
Intervention: Thyme honey
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study: 26352854

Group type: EXPERIMENTAL
Intervention: m-health+CP (automated feedback to CarePartners)
Number of subjects: 72

Group type: COMPARATOR
Intervention: standard m-health (IVR calls without CarePartner feedback)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: m-health+CP
Number of subjects: 72
Study: 25170012

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard of care (docetaxel or pemetrexed)
Number of subjects: 347
Study: 22669546

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene (XLPE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional polyethylene (PE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XLPE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19467368

Group type: EXPERIMENTAL
Intervention: 32 U BoNTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 64 U BoNTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 96 U BoNTA
Number of subjects: 60
Study: 17498014

Group type: EXPERIMENTAL
Intervention: Audiovisual information (8-minute video)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard preoperative preparation (Control)
Number of subjects: 111
Study: 15005434

Group type: EXPERIMENTAL
Intervention: In vivo axial
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: In vivo gingival
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: In vitro axial
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: In vitro gingival
Number of subjects: 14
Study: 11779724

Group type: EXPERIMENTAL
Intervention: Budesonide (1,600 or 3,200 microg/d) for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Budesonide (1,600 microg/d) after initial treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 35
Study: 9737754

Group type: EXPERIMENTAL
Intervention: Water temperature at 41.5 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water temperature at 40.0 degrees C
Number of subjects: 6
Study: 8126354

Group type: EXPERIMENTAL
Intervention: Multisensory balance training
Number of subjects: 24
Study: 2782749

Group type: EXPERIMENTAL
Intervention: Albuterol 200 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 1,500 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 500 micrograms
Number of subjects: 8
Study: 1085495

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery
Number of subjects: 58
Study: 31146543

Group type: EXPERIMENTAL
Intervention: Art intervention
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Integration of art and Qigong
Number of subjects: 267

Group type: COMPARATOR
Intervention: Qigong intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Integrated intervention (art and Qigong)
Number of subjects: 267
Study: 26760574

Group type: EXPERIMENTAL
Intervention: Dry needling on the most hyperalgesic active and latent MTrP
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dry needling only on the most hyperalgesic active MTrP
Number of subjects: 66
Study: 27825008

Group type: EXPERIMENTAL
Intervention: Donor milk
Number of subjects: 363

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 363
Study: 25470133

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EC)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 500
Study: 22589297

Group type: EXPERIMENTAL
Intervention: Interhospital transfer for primary percutaneous coronary intervention
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: D1D2 time ≤150 minutes
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: D1D2 time >150 minutes
Number of subjects: 2075
Study: 21055142

Group type: EXPERIMENTAL
Intervention: felodipine 5 mg q.d + irbesartan 150 mg q.d (F + I group, n = 49)
Number of subjects: 99

Group type: COMPARATOR
Intervention: felodipine 5 mg q.d + metoprolol 47.5 mg q.d (F + M group, n = 50)
Number of subjects: 99
Study: 18212287

Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs)
Number of subjects: 3958

Group type: COMPARATOR
Intervention: No embolic protection devices (EPDs)
Number of subjects: 3958
Study: 15749489

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 38
Study: 12886670

Group type: EXPERIMENTAL
Intervention: Exercise group taking placebos (EGP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Exercise group taking vitamin E (EGE)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sedentary group taking vitamin E (SGE)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sedentary group taking placebos (SGP)
Number of subjects: 59
Study: 11030506

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ergonomics
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Rehabilitation and ergonomics
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 8971321

Group type: EXPERIMENTAL
Intervention: Optiva polyurethane cannula
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Insyte polyurethane cannula
Number of subjects: 1008
Study: 1336516

Group type: EXPERIMENTAL
Intervention: ROM version 1.22
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ROM version 1.24
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ROM version 1.28
Number of subjects: 14

Group type: COMPARATOR
Intervention: ROM version 1.22 and 1.24
Number of subjects: 14
Study: 3901207

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: cefotaxime
Number of subjects: 31
Study: 31355286

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (4 doses)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Birth dose of Hepatitis B vaccine
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Factors influencing vaccination
Number of subjects: 768
Study: 29537447

Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.0%
Number of subjects: 445

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 445
Study: 26747220

Group type: EXPERIMENTAL
Intervention: Skin glue (cyanoacrylate) applied to the skin insertion site with standard securement
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard securement (control group)
Number of subjects: 360
Study: 24431911

Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Voglibose (0.9 mg/day)
Number of subjects: 121
Study: 22951790

Group type: EXPERIMENTAL
Intervention: 380 mg XR‐NTX
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 20307032

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone injection
Number of subjects: 63

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined radial optic neurotomy/intraocular triamcinolone injection
Number of subjects: 63
Study: 18559703

Group type: EXPERIMENTAL
Intervention: HGF plasmid (high dose: 4.0 mg at days 0, 14, and 28)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HGF plasmid (low dose: 0.4 mg at days 0, 14, and 28)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HGF plasmid (middle dose: 4.0 mg at days 0 and 28)
Number of subjects: 104
Study: 15753793

Group type: EXPERIMENTAL
Intervention: Tl SPECT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LDDE
Number of subjects: 26
Study: 11952265

Group type: EXPERIMENTAL
Intervention: Children (6-12 years)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 78
Study: 10326954

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 19
Study: 7847516

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 micrograms of estradiol daily) with levonorgestrel-releasing intrauterine device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral estrogen (2 mg of estradiol valerate and 1 mg of norethisterone acetate daily)
Number of subjects: 40
Study: 1752280

Group type: EXPERIMENTAL
Intervention: M‐VAC (modified methotrexate, vinblastine, adriamycin and cisplatin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: MP (methotrexate followed by folinic acid rescue and cisplatin)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: M‐VAC
Number of subjects: 28

Group type: COMPARATOR
Intervention: MP
Number of subjects: 28
Study: 7074558

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, cyclophosphamide, doxorubicin, and 5-fluorouracil (MCAF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MCA
Number of subjects: 12

Group type: COMPARATOR
Intervention: MCAF
Number of subjects: 12
Study: 31994751

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) knee implant
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) knee implant
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Medial-stabilized (MS) knee implant
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy knee
Number of subjects: 74
Study: 31498414

Group type: EXPERIMENTAL
Intervention: Individually customized IOL (HumanOptics AG, Erlangen, Germany)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard spherical aberration-correcting IOL (Tecnis ZCB00; Johnson & Johnson Vision Surgical, Inc., Santa Ana, CA)
Number of subjects: 60
Study: 28236615

Group type: EXPERIMENTAL
Intervention: Listening to music and exercise training (MT) group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Exercise training only (T) group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Listening to music only (M) group
Number of subjects: 74
Study: 26310261

Group type: EXPERIMENTAL
Intervention: Intravenous elafin 200 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 87
Study: 24316098

Group type: EXPERIMENTAL
Intervention: Gastroretentive double-layered tablet formulation (GSS)
Number of subjects: 9
Study: 22724877

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg capsules, three times daily until end of chemotherapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (three placebo capsules daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 50
Study: 19685943

Group type: EXPERIMENTAL
Intervention: Happy mood induction night
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sad mood induction night
Number of subjects: 28
Study: 17462083

Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention programme
Number of subjects: 513
Study: 15175869

Group type: EXPERIMENTAL
Intervention: Preplanning based on pretherapeutic transrectal ultrasound for the first HDR brachytherapy implant.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Preplanning based on ultrasound from the first HDR brachytherapy implant for the second HDR brachytherapy.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Postplans compared to preplans for both HDR brachytherapy implants.
Number of subjects: 15
Study: 11937460

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Maximum medical therapy
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Percutaneous transmyocardial laser revascularization (PMR)
Number of subjects: 6000
Study: 11475718

Group type: EXPERIMENTAL
Intervention: Weihuigui Decoction (WHGD) 100 ml, three times a day for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 64
Study: 10332645

Group type: EXPERIMENTAL
Intervention: Sun protection program including curricular materials, training and support for staff, and parent outreach.
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Sun protection program
Number of subjects: 4200
Study: 2068471

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 6861846

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg p.o.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine (20 mg thrice daily)
Number of subjects: 9
Study: 30897983

Group type: EXPERIMENTAL
Intervention: Dexpanthenol-containing ointment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Petroleum jelly
Number of subjects: 38
Study: 29275906

Group type: COMPARATOR
Intervention: Stress management training (n=65) including self-awareness, focus, relaxation, positive self-talk, visualization, and team building.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (n=72) without stress management training.
Number of subjects: 137
Study: 26841799

Group type: EXPERIMENTAL
Intervention: COTiD-UK
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual (VALID programme)
Number of subjects: 480
Study: 25223320

Group type: EXPERIMENTAL
Intervention: GtxA-N
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FlfA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gab_1309
Number of subjects: 0
Study: 22306394

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Number of subjects: 123
Study: 20169359

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 24
Study: 18086763

Group type: EXPERIMENTAL
Intervention: Culturally appropriate breast cancer education program
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 776
Study: 15763533

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bradycardia prevention pacing (BPP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No pacing (NP)
Number of subjects: 124
Study: 12016079

Group type: EXPERIMENTAL
Intervention: Passive positioning of the shoulder in midrange positions
Number of subjects: 6
Study: 9257738

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily from day -2 to day 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily from day -2 to day 0)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sparfloxacin alone (400 mg single oral dose on day 0)
Number of subjects: 15
Study: 8290678

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Benztropine (6 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3579261

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (40 mg/kg per day) for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 100
Study: 29888939

Group type: EXPERIMENTAL
Intervention: Updating training
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Item-to-context binding training
Number of subjects: 197

Group type: COMPARATOR
Intervention: Active control group practicing visual search tasks
Number of subjects: 197
Study: 28033691

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day for week 1; 20 mg/day for weeks 2-6) plus olanzapine (15-20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 0
Study: 24448288

Group type: EXPERIMENTAL
Intervention: Early (1-wk) switch-on group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (switch-on after 4 wks)
Number of subjects: 17
Study: 22076437

Group type: EXPERIMENTAL
Intervention: Low to moderate doses of lithium
Number of subjects: 283

Group type: COMPARATOR
Intervention: No lithium (control group)
Number of subjects: 283
Study: 20663600

Group type: EXPERIMENTAL
Intervention: Coronectomies with endodontic treatments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Coronectomies without endodontic treatment
Number of subjects: 10
Study: 17997267

Group type: EXPERIMENTAL
Intervention: Twice-weekly vouchers to reinforce abstinence and positive behaviors
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 163
Study: 16393332

Group type: EXPERIMENTAL
Intervention: Periodic administration of penicillin G and V (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No repeated penicillin administration (Group B)
Number of subjects: 20